David A. Garcia

TL;DR: In patients with atrial fibrillation who had warfarin treatment interrupted for an elective operation or other elective invasive procedure, forgoing bridging anticoagulation was noninferior to perioperative bridging with low-molecular-weight heparin for the prevention of arterial thromboembolism and decreased the risk of major bleeding.

TL;DR: Clinical guidance is provided based on existing guidelines and consensus expert opinion where guidelines are lacking on the appropriate workup to search for occult malignancy in patients with idiopathic VTE.

TL;DR: Among patients in ARISTOTLE, the 30-day postprocedure stroke, death, and major bleeding rates were low and similar in apixaban- and warfarin-treated patients, regardless of whether anticoagulation was stopped beforehand.

TL;DR: There are some situations in which assessment of anticoagulant effect may aid treatment decisions and the specialized coagulation assays that have been developed to measure the anticoaggulant effects of the new oral antICOagulants are identified.

TL;DR: Although a positive APLA test appears to predict an increased risk of recurrence in patients with a first VTE, the strength of this association is uncertain because the available evidence is of very low quality.